Treprostinil
Treprostinil is an active ingredient of the class «antithrombotic».
Chemical compound
What it is used for
- Pulmonary hypertension
- Chronic pulmonary heart disease
- Thrombosis
- Arterial pulmonary hypertension
Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
Treatment of adult patients with WHO Functional Class (FC) III or IV and: inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment to improve exercise capacity.
How it works
- Prostanoid IP receptor agonist
Class: antithrombotic
Common side effects
Most common adverse reactions (≥4%) are cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, diarrhea, and syncope.
Pregnancy and breastfeeding
Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.
Interactions
Brand names
United States
Orenitram · Remodulin · Tyvaso · Tyvaso DPI
European Union
Trepulmix
Canada
Remodulin
Other trade names
Ut-15c
Approval status
- US Food and Drug Administration
- prescription · since 2002
- European Medicines Agency
- authorised · since 2020
- Health Canada
- prescription · marketed
- First approval anywhere
- 2002
Codes
- ATC
- B01AC21
- RxNorm CUI
- 343048
- ChEMBL
- CHEMBL1237119
- PubChem CID
- 6918140
- UNII
- RUM6K67ESG
- Wikidata
- Q3495231
Frequently asked questions
What is Treprostinil used for?
Treprostinil is used for: Pulmonary hypertension, Chronic pulmonary heart disease, Thrombosis, and Arterial pulmonary hypertension.
What kind of medicine is Treprostinil?
Treprostinil is an active ingredient of the class «antithrombotic».
What are the brand names of Treprostinil?
Brand names of Treprostinil include Orenitram, Remodulin, Tyvaso, Tyvaso DPI, Trepulmix, and Ut-15c.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)